Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Court rejects brand‑maker’s inducement claim against a generic drug maker, making it harder for drug companies to sue generics over labels, websites, and press releases and protecting skinny‑labeled generics.
Holding
Amarin failed to plausibly allege that Hikma took affirmative steps to encourage others to use its generic for Amarin’s patented heart‑risk use, so the induced‑infringement claim cannot survive dismissal.
Real-world impact
- Limits when brand companies can sue generics for inducing patented drug uses.
- Protects generic makers relying on skinny labels and routine marketing statements.
- Keeps prescribing decisions by doctors outside routine liability for generics.
Topics
Summary
Background
Amarin is the maker of Vascepa, which the FDA originally approved for a rare high‑triglyceride condition and later for a common heart‑risk use for patients on statins. Amarin obtained patents for that heart‑risk use. Hikma is a generic manufacturer that sought approval for a skinny label covering only the unpatented use; the FDA approved Hikma’s generic with an AB equivalence rating. Amarin sued, saying Hikma’s skinny label, patient leaflet, website, and press releases together actively encouraged doctors and pharmacists to use the generic for the still‑patented heart‑risk purpose.
Reasoning
The Court’s question was whether Hikma took affirmative steps to encourage infringement, not just whether doctors might read Hikma’s materials in a certain way. The Court explained inducement requires intentional, affirmative acts designed to cause infringement; ordinary compliance with law, routine industry descriptions, omissions, or vague statements do not meet that bar. The Court found Hikma’s statements had obvious lawful explanations (statutory labeling requirements and normal industry practice), that omissions cannot substitute for affirmative encouragement, and that the remaining statements were too vague and speculative to plausibly show intentional inducement.
Real world impact
Because the Court held Amarin did not plausibly plead affirmative encouragement, the complaint cannot survive a motion to dismiss and the case returns to the lower courts for further proceedings consistent with this standard. The ruling makes it harder for brand companies to turn routine generic labeling, disclosures, or promotional statements into grounds for inducement liability, though future facts or evidence could change the outcome at later stages.
Questions, answered
Ask questions about the entire case, including all opinions (majority, concurrences, dissents). Try:
- “What was the Court's main decision and reasoning?”
- “How did the dissenting opinions differ from the majority?”
- “What are the practical implications of this ruling?”